XORTX Therapeutics Inc. (XRTX.V)

CAD 1.38

(-5.48%)

Gross Profit Summary of XORTX Therapeutics Inc.

XORTX Therapeutics Inc.'s latest annual gross profit in 2023 was -188.54 Thousand CAD , down -150.5% from previous year.
XORTX Therapeutics Inc.'s latest quarterly gross profit in 2024 Q2 was - USD , up 100.0% from previous quarter.
XORTX Therapeutics Inc. reported a annual gross profit of -75.26 Thousand CAD in annual gross profit 2022, down -320.91% from previous year.
XORTX Therapeutics Inc. reported a annual gross profit of -17.88 Thousand CAD in annual gross profit 2021, up 12.51% from previous year.
XORTX Therapeutics Inc. reported a quarterly gross profit of - USD for 2024 Q2, up 100.0% from previous quarter.
XORTX Therapeutics Inc. reported a quarterly gross profit of -43 Thousand USD for 2023 Q2, up 52.44% from previous quarter.

Annual Gross Profit Chart of XORTX Therapeutics Inc. (2023 - 2014)

Historical Annual Gross Profit of XORTX Therapeutics Inc. (2023 - 2014)

Year	Gross Profit	Gross Profit Growth
2023	-188.54 Thousand CAD	-150.5%
2022	-75.26 Thousand CAD	-320.91%
2021	-17.88 Thousand CAD	12.51%
2020	-20.43 Thousand CAD	-2.71%
2019	-19.9 Thousand CAD	-3.02%
2018	-19.31 Thousand CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	0.0%
2014	- CAD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q1	-43.33 Thousand USD	-30.61%
2024 Q2	- USD	100.0%
2023 Q2	-43 Thousand USD	52.44%
2023 FY	-188.54 Thousand CAD	-150.5%
2023 Q3	-22.08 Thousand USD	48.64%
2023 Q4	-33.17 Thousand USD	-50.22%
2023 Q1	-90.41 Thousand USD	-209.16%
2022 Q2	-12.45 Thousand CAD	-160.49%
2022 Q1	-4781.00 CAD	-0.89%
2022 Q4	-29.24 Thousand CAD	-1.59%
2022 Q3	-28.78 Thousand CAD	-131.15%
2022 FY	-75.26 Thousand CAD	-320.91%
2021 FY	-17.88 Thousand CAD	12.51%
2021 Q4	-4739.00 CAD	-4.71%
2021 Q2	-4373.00 CAD	-3.04%
2021 Q1	-4244.00 CAD	0.0%
2021 Q3	-4526.00 CAD	-3.5%
2020 Q4	- CAD	0.0%
2020 Q2	- CAD	0.0%
2020 Q1	- CAD	0.0%
2020 FY	-20.43 Thousand CAD	-2.71%
2020 Q3	- CAD	0.0%
2019 Q1	- CAD	0.0%
2019 FY	-19.9 Thousand CAD	-3.02%
2019 Q2	- CAD	0.0%
2019 Q4	- CAD	0.0%
2019 Q3	- CAD	0.0%
2018 Q1	- CAD	0.0%
2018 Q4	- CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 FY	-19.31 Thousand CAD	0.0%
2017 Q1	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 Q3	- CAD	0.0%
2017 Q2	- CAD	0.0%
2016 FY	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q1	- CAD	0.0%
2015 Q1	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q3	- CAD	0.0%
2014 Q3	- CAD	0.0%
2014 FY	- CAD	0.0%
2014 Q2	- CAD	0.0%
2014 Q4	- CAD	0.0%

Peer Gross Profit Comparison of XORTX Therapeutics Inc.

Name	Gross Profit	Gross Profit Difference
Arch Biopartners Inc.	-128.99 Thousand CAD	-46.166%
Covalon Technologies Ltd.	14.36 Million CAD	101.313%
Hemostemix Inc.	-223.00 CAD	-84448.43%
Universal Ibogaine Inc.	1.07 Million CAD	117.608%
Kane Biotech Inc.	109.47 Thousand CAD	272.233%
MedMira Inc.	-434.91 Thousand CAD	56.648%
Marvel Biosciences Corp.	-887.51 Thousand CAD	78.756%
NervGen Pharma Corp.	-145 Thousand CAD	-30.027%